secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001171843-24-002591
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M
-------------------------------------------------------------------------------

- Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.
- GAAP net loss $4.7M ($0.11 loss per share) vs net income $0.6M ($0.01 EPS) a year ago.
- Adjusted operating income $1.2M, down from $4.4M; adjusted EBITDA $1.6M, down from $4.8M.
- CEO cites APAC market headwinds and strong prior-year comp; cost reduction initiative announced post-quarter.
- Expects solid growth in second half aided by new product launches and Chinese stimulus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/0001171843-24-002591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/f8k_050724.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer